<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014456</url>
  </required_header>
  <id_info>
    <org_study_id>D9933</org_study_id>
    <secondary_id>P30CA023108</secondary_id>
    <secondary_id>DMS-9933</secondary_id>
    <secondary_id>NCI-G01-1933</secondary_id>
    <nct_id>NCT00014456</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgrastim (NEUPOGEN) For The Treatment Of Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Colony-stimulating factors such as filgrastim may increase the
      number of immune cells found in bone marrow or peripheral blood and may help a person's
      immune system recover from the side effects of chemotherapy.

      PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus filgrastim
      in treating patients who have advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of docetaxel in combination with gemcitabine and
           filgrastim (G-CSF) in patients with advanced solid tumors.

        -  Determine the dose-limiting toxicity associated with this regimen in these patients.

        -  Assess the objective anti-tumor response in patients treated with this regimen.

        -  Determine fatigue and blood cytokines in patients treated with this regimen.

      OUTLINE: This is a dose-escalation study of docetaxel.

      Patients receive docetaxel IV over 1 hour followed by gemcitabine IV over 30 minutes on day
      1. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 2 and
      continuing until blood counts recover. Treatment repeats every 14 days in the absence of
      disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
      of 6 patients experience dose-limiting toxicity.

      Fatigue is assessed at baseline and then at weeks 2, 5, 7, and 9 during therapy.

      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 15-22
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">October 2005</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximal tolerated dose of docetaxel in combination with gemcitabine given intravenously every 2 weeks with pegfilgrastim support</measure>
    <time_frame>Four years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Define dose limiting adverse events associated with the combination</measure>
    <time_frame>Four years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective antitumor response</measure>
    <time_frame>Four years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">35</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Carcinoma of Unknown Primary</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed advanced solid tumor that is not curable by
             surgery or radiotherapy

               -  Sarcoma

               -  Melanoma

               -  Carcinoma of unknown primary

               -  Pancreatic cancer

               -  Lung cancer

               -  Ovarian cancer

               -  Breast cancer

               -  Bladder cancer

               -  Gastric cancer

               -  Esophageal cancer

               -  Prostate cancer

               -  Head and neck cancer

          -  No hematopoietic or lymphoid tumors

          -  Measurable or evaluable disease

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  Karnofsky 60-100%

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,000/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin normal

          -  AST and/or ALT no greater than 5 times upper limit of normal (ULN) if alkaline
             phosphatase no greater than ULN OR

          -  Alkaline phosphatase no greater than 5 times ULN if AST and ALT no greater than ULN OR

          -  AST and/or ALT no greater than 1.5 times ULN if alkaline phosphatase no greater than
             2.5 times ULN

        Renal:

          -  Creatinine no greater than 2 times ULN OR

          -  Creatinine clearance at least 50 mL/min

        Cardiovascular:

          -  No congestive heart failure

          -  No unstable angina

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No uncontrolled infection

          -  No known sensitivity to E. coli-derived products

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 2 weeks since prior cytotoxic anti-tumor therapy (4 weeks for nitrosourea or
             mitomycin) and recovered

          -  No prior docetaxel or gemcitabine

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

          -  At least 2 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin H. Dragnev, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Dragnev KH, Hardin SB, Pipas JM, Davis TH, Rigas JR. A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. Chemotherapy. 2010;56(2):135-41. doi: 10.1159/000313526. Epub 2010 Apr 20.</citation>
    <PMID>20407240</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>chondrosarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>extensive stage small cell lung cancer</keyword>
  <keyword>recurrent small cell lung cancer</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>classic Kaposi sarcoma</keyword>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

